Skip to main content

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In What does "Remember Me" do?

Don't Know Your Password?
Help

Join Now
Sign In

Member Sign In

Username or Email Address

Password

Keep Me Signed In

Don't Know Your Password?

Zacks

more

Adaptimmune Therapeutics (ADAP)

(Delayed Data from NSDQ)

$0.98 USD

+0.08 (8.72%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $0.97 -0.01 (-0.69%) 6:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	18.00%
3	Hold	9.44%
4	Sell	5.10%
5	Strong Sell	2.53%
S&P	500	11.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

View Cart/Checkout

Adaptimmune Therapeutics PLC [ADAP]

Reports for Purchase

Showing records 1 - 20 ( 123 total )

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 1

10/25/2023

Pages: 4

Biotechnology -Healthcare Coverage Update

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 2

03/06/2023

Industry Report

Pages: 4

Event Driven A.M. Note

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 3

11/08/2022

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 4

11/08/2022

Pages: 6

3Q22: Lead Product''s Rolling BLA Submission Begins in December. Updated Responses in SURPASS

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 5

11/08/2022

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 6

11/08/2022

Pages: 6

3Q22: Lead Product''s Rolling BLA Submission Begins in December. Updated Responses in SURPASS

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 7

11/02/2022

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 8

11/01/2022

Pages: 4

Ovarian Cancer Trial Posted on Clinicaltrials.gov

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 5.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 9

10/26/2022

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 10

10/25/2022

Pages: 6

GSK Returns Assets. Is This an Opportunity?

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 11

09/28/2022

Industry Report

Pages: 12

Our Inaugural Healthcare Opportunities Conference in New York City on October 6th

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 12

09/22/2022

Industry Report

Pages: 12

Our Inaugural Healthcare Opportunities Conference in New York City on October 6th

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 12.50

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 13

09/09/2022

Pages: 7

SURPASS Data Support a Pipeline in a Product Against Solid Tumors--PT $10

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 14

09/09/2022

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 15

09/06/2022

Pages: 4

SURPASSing the Solid Tumor Challenge with the Second Gen TCR: Virtual Event During ESMO

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 5.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 16

09/06/2022

Industry Report

Pages: 3

ESMO 2022 Abstracts Released

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 5.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 17

09/06/2022

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 18

08/04/2022

Pages: 4

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 19

08/04/2022

Pages: 6

2Q22: Judicious Resource Allocation to Progress Platform. First Regulatory Submission in Q422

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Company: Adaptimmune Therapeutics PLC

Industry: Medical - Biomedical and Genetics

Record: 20

05/27/2022

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

previous
1
2
3
4
5
6
7
next